Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Other Non-Current Liabilities (2016 - 2024)

Historic Other Non-Current Liabilities for Voyager Therapeutics (VYGR) over the last 10 years, with Q3 2024 value amounting to $39.4 million.

  • Voyager Therapeutics' Other Non-Current Liabilities rose 10808.71% to $39.4 million in Q3 2024 from the same period last year, while for Sep 2024 it was $39.4 million, marking a year-over-year increase of 10808.71%. This contributed to the annual value of $18.1 million for FY2023, which is 1503.17% down from last year.
  • According to the latest figures from Q3 2024, Voyager Therapeutics' Other Non-Current Liabilities is $39.4 million, which was up 10808.71% from $41.2 million recorded in Q2 2024.
  • Voyager Therapeutics' 5-year Other Non-Current Liabilities high stood at $44.4 million for Q4 2020, and its period low was $18.1 million during Q4 2023.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $31.1 million (2020), whereas its average is $31.9 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first crashed by 4629.86% in 2022, then soared by 10951.17% in 2024.
  • Voyager Therapeutics' Other Non-Current Liabilities (Quarter) stood at $44.4 million in 2020, then dropped by 10.81% to $39.6 million in 2021, then tumbled by 46.24% to $21.3 million in 2022, then dropped by 15.03% to $18.1 million in 2023, then soared by 117.57% to $39.4 million in 2024.
  • Its Other Non-Current Liabilities stands at $39.4 million for Q3 2024, versus $41.2 million for Q2 2024 and $43.0 million for Q1 2024.